Evotec stock at EUR 2.77 ahead of the Xetra open: drug group rises 1.84 percent
Published on 10/21/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness model and market context
- Evotec develops medicines with partners through data science, artificial intelligence and drug research.
- The German market context is the DAX on October 21, 2026.
- Evotec stock trades pre-market at EUR 2.77 at 7:46 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.84 percent above the Xetra close of October 20, 2026.
Evotec SE develops medicines with partners using data science, artificial intelligence and drug-research technologies, according to its investor-relations page. Evotec stock trades pre-market at EUR 2.77 at 7:46 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.84 percent above the Xetra close of October 20, 2026 (EUR 2.72).
Morning price check
The move equals plus EUR 0.05, leaving the quote above the reference level. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Evotec stock.
How Evotec earns revenue
Evotec earns revenue through drug-discovery partnerships, milestone payments, licenses and revenue-sharing arrangements, alongside biologics development and manufacturing, as described by the company’s investor-relations page. The German market context is the DAX on October 21, 2026.
Market context: Market report DAX.
